tak-861
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jan 9, 2023 (NCT05687916)
Timeline
Indications
Studied for
Mechanism of action
- Orexin receptor 2AGONIST
HCRTR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06505031 | Phase 3 | Nov 15, 2024 | Takeda |
| NCT06470828 | Phase 3 | Jul 2, 2024 | Takeda |
| NCT05816382 | Phase 2/Phase 3 (Phase 3) | Apr 5, 2023 | Takeda |
| NCT05687903 | Phase 2 | Jan 9, 2023 | Takeda |
| NCT05687916 | Phase 2 | Jan 9, 2023 | Takeda |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 5 | 5 | 2 | 2023 |
1 organizations
Page 1 / 1